DERMAL TOXICITY

Gentronix offers a wide range of predictive genotoxicity assays designed and developed to enable rapid, accurate and low compound screening within your R&D programme.

SERVICE INFORMATION

Using our knowledge, background and expertise in screening, we have established a comprehensive portfolio of services for the identification of genotoxic hazard. Our BlueScreen™ HC assay provides a low compound requiring, high-throughput and highly accurate prediction of in vivo genotoxic potential. Our Ames and in vitro micronucleus screening options provide you with an efficient and effective prediction of the regulatory test guideline outcome, with our experts guiding you to select the most appropriate assay types and combination. In addition, we offer a range of screens that enable genotoxic hazard to be contextualised, enabling mode of action opposite potential mutagens, clastogens and aneugens to be quickly and accurately determined. We look forward to supporting your next screening project.

Bluescreen / Greenscreen

BlueScreen™ HC and GreenScreen® HC are high-throughput gene reporter assays, developed by Gentronix, which measure increased transcription of GADD45-alpha – a key event in the cellular response to genotoxic stress and damage.

Read More

AMES

Gentronix offers a range of screening options to help our clients to assess the mutagenic potential of test substances in the Ames test.

Read More

Micronucleus Test

Gentronix offers a range of screening options for the assessment of a test substance in the micronucleus test, and its potential to induce structural and numerical chromosomal damage.

Read More

Mechanistic

Gentronix offers a number of assay tools to enable our team of experts to work with you to understand toxicology challenges, establish a mode of action by determining mechanism and supporting you in managing hazard.

Read More

Predictive Toxicology, Expertly Delivered